Skip to main content
. 2016 Jan 13;24(8):1167–1174. doi: 10.1038/ejhg.2015.281

Figure 1.

Figure 1

Example of genomic profiles from DNAs extracted from FFPE and cellular and cfDNA from the urine from patient 23 with a stage G2 pT1 NMIBC. Comparison of profiles shows consistent aberrations identified in all three samples (red=loss, blue=gain and yellow=LOH). Aberrations from all three sources show homozygous loss at 9p21.3 including CDKN2A/B; listed in the TARGET database. Biallelic inactivation of CDKN2A/B may predict response to CDK4/6 inhibitors for this patient.